Consulting, Outsourcing, and Software
for the Life Sciences industry

We empower our clients by delivering innovative solutions that provide efficiency, clarity, and accelerated insights.

Learn More

How We Can Help

At Riparian, we believe that solutions originate when we listen, understand, and deliver together as one team.
Let our team of Technology and Subject Matter Experts be an extension of your team.


Our technology services cover the full system development life cycle from providing the solution (ranked Top 10 Enterprise Solution Provider by PharmaTech Outlook magazine), to implementing the solution, to providing ongoing support.

Learn More


Our consulting services cover a broad range of matters at the intersection of strategy, compliance/risk, and reward. We perform complex data analysis and identify opportunities for enhancements to business operations and systems.

Learn More


Our managed services or outsourcing allows manufacturers at all stages of maturity to optimize their resources by leveraging industry experts to identify, implement, and execute best practices for critical business operations.

Learn More

Our Leadership Team

David S Chan

Co-Founder and CEO

David has overall responsibility for the strategic direction of Riparian, product development and specific client initiatives. David brings 19+ years of experience leading advisory teams in the life sciences.

Cynthia Hwang

Co-Founder and Senior Vice President

Cynthia has 18+ years of experience advising a variety of clients in the life sciences industry – including generic drug manufacturers, “traditional” brand drug manufacturers, and manufacturers of specialty therapeutics (including gene therapy).

Don Russell

Sr Director, Managed Services

With more than seventeen years of pharmaceutical industry and managed services experience, Don’s primary concentration has been in Government price reporting, program contracting and rebate adjudication. Prior to joining Riparian, Don was Practice Leader for Deloitte Advisory Managed Risk Services leading the Government and Commercial rebates and fees practice.

Timothy Nugent, CPA

Sr Director, Consulting and Managed Services

Providing over 25+ years experience in revenue management consulting to the Life Science industry. The experience and expertise Tim offers was developed through successful implementing and maintaining working relationships with 100+ large, medium and small manufacturers to address their regulatory, compliance and operational revenue management issues both commercial and government.

Luca Bernardo Ciddio

Sr Software Architect

Luca has 15+ years of software engineering experience working with companies of all sizes in three countries, and has been writing software for three decades. With a strong background in computer science, security and AI, he is currently responsible for the overall architecture and innovation of our flagship SaaS platform.


COVID Part 2: How Can the Effects of COVID-19 Create Shifts in Market Segmentation & 340B Covered Entities?

Riparian Article

While the life sciences industry is on the front lines of battle against COVID-19 working on vaccinations and treatments to combat the virus, manufacturers must understand and prepare for how the shifts in demand and patient populations will impact their Government Program liabilities and Gross-to-Net.

COVID Part 1: How Can the Macroeconomic Effects of COVID-19 Impact Medicaid Liabilities and Accrual Forecasting?

Riparian Article

Undoubtedly, COVID-19 will leave an unprecedented impact on our economy for months, if not years, to come. While the life sciences industry is on the front lines of battle against COVID-19 working on vaccinations and treatments to combat the virus, manufacturers must understand and prepare for the potentially significant financial implications to their Government Programs.

Inflation-Based Rebates for Medicare Part B and Part D Covered Drugs

Distinctions Between Congressional Bills H.R.3 and S.2543

There are similar provisions in both bills, but relevant to pharmaceutical manufacturers, both introduce an inflation-based rebate for Medicare Part B and Part D covered drugs.

Managing Medicaid Spend Through Supplemental Rebates

White Paper

Medicaid expenditures have increased significantly over the last decade and states are looking for novel approaches to help control costs while maintaining access to drugs.

Pharma Tech Outlook 2018

Top 10 Enterprise Software Solution Providers 2018

Pharma Tech Outlook 2019

Top 10 Enterprise Software Solution Providers 2019

CIO Review

10 Most Promising Healthcare Tech Startups - 2019

Let's Get in Touch

Drop a line and let's get the conversation started.




Headquartered in Pasadena, CA